Cardio Diagnostics Holdings Inc., an AI-powered precision cardiovascular medicine company, has announced a significant milestone in its regulatory journey with the Centers for Medicare and Medicaid Services $(CMS)$. The CMS, through the MolDX program, has issued preliminary gapfill payment rates for Cardio Diagnostics' AI-driven cardiovascular tests. The rates are set at $350 for the Epi+Gen CHD™ test and $684.76 for the PrecisionCHD™ test. This development is a crucial step toward expanding access to Medicare reimbursement, enhancing care for Medicare beneficiaries at risk for coronary heart disease. These rates are expected to be finalized later this year and will be effective for claims with dates of service on or after January 1, 2025. The approval is solely for Cardio Diagnostics Holdings Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.